Sunday - October 4, 2026
Goodwin Advises Hengrui on Intellectual Property Aspects of Exclusive License Agreement with Novo for Up to $2.6 Billion
October 01, 2026
BOSTON, Massachusetts, Oct. 1 [Category: BizLaw/Legal] -- Goodwin, a law firm, posted the following news release:

* * *

Goodwin Advises Hengrui on Intellectual Property Aspects of Exclusive License Agreement with Novo for Up to $2.6 Billion

*

The Life Sciences team advised Hengrui on the intellectual property aspects of entering into a license agreement with Novo Nordisk ("Novo") for HRS-1596, a phase I-ready glucagon-like peptide-1 r . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products